Suppression of the proliferation marker Ki-67 has been previously reported as a surrogate marker for decreased aromatase activity in oestrogen receptor (ER) positive breast cancer treated with aromatase inhibitors (AI) for two weeks [48,49]. The gene discussed is MKI67; the disease is breast carcinoma.